行情

BMRN

BMRN

拜玛林制药
NASDAQ

实时行情|Nasdaq Last Sale

119.65
-0.18
-0.15%
盘后: 119.65 0 0.00% 16:09 08/06 EDT
开盘
119.60
昨收
119.83
最高
120.66
最低
118.36
成交量
64.26万
成交额
--
52周最高
131.95
52周最低
62.88
市值
216.37亿
市盈率(TTM)
196.02
分时
5日
1月
3月
1年
5年

分析师评级

24位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BMRN价格均价为133.91,最高价位172.00,最低价为108.00。

EPS

BMRN 新闻

更多
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Zacks · 1天前
How Biomarin Beat Expectations in Q2
You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. Here are the highlights from BioMarin's Q2 update. The company announced a net loss in the second quarter of $29.2 million, or $0.16 pe
Motley Fool · 1天前
Biomarin Pharmaceutical Inc (BMRN) Q2 2020 Earnings Call Transcript
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. includin
Motley Fool · 1天前
BioMarin Pharmaceutical EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit
BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04. Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M. For the FY20, BioMarin conti
seekingalpha · 2天前
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2天前
Lion Biotechnologies Reaches 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
Investor's Business Daily · 2天前
Biomarin Pharmaceutical Q2 EPS $(0.16) Misses $(0.11) Estimate, Sales $429.50M Beat $418.61M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per
Benzinga · 2天前
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
PR Newswire · 2天前

所属板块

制药
-0.28%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

BMRN 简况

BioMarin Pharmaceutical Inc.主要从事开发和产业化用于治疗各种疾病和改善医疗条件的药品业务。该公司的产品组合包括五个已批准产品,以及多个临床和临床前产品。已批准产品包括Vimizim(elosulfase alpha)、Naglazyme(galsulfase)、Kuvan(sapropterin二盐酸盐)、Aldurazyme(laronidase)和Firdapse(磷酸氨吡啶)。临床开发产品包括Kyndrisa、Pegvaliase、葡萄糖苷酶、Vosoritide(前称BMN 111)、Cerliponase alfa、BMN 044、BMN 045、BMN 053和BMN 270。Vimizim是用于治疗IV型黏多糖病(MPS IV)的替代酶。Naglazyme是用于治疗MPS IV的N-乙酰氨基半乳糖4-硫酸酯酶的重组体。Kuvan是用于治疗苯丙酮尿症(PKU)的6R-BH4的合成口服药。
展开

微牛提供BioMarin Pharmaceutical Inc.(NASDAQ-BMRN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BMRN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BMRN股票基本功能。